

Neil S Horowitz

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4719464/neil-s-horowitz-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

104
papers

2,032
citations

23
h-index

42
g-index

119
ext. papers

2,757
ext. citations

4
avg, IF

4.86
L-index

#	Paper	IF	Citations
104	A phase I study of AZD2171 and Teme sirolimus in patients with advanced gynecological malignancies.. <i>Cancer Chemotherapy and Pharmacology</i> , 2022 , 89, 423	3.5	
103	Consolidation chemotherapy in postmolar low-risk gestational trophoblastic neoplasia: a systematic review protocol.. <i>BMJ Open</i> , 2022 , 12, e059484	3	
102	A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma.. <i>Gynecologic Oncology Reports</i> , 2022 , 40, 100974	1.3	1
101	Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. <i>Cancer Research</i> , 2021 , 81, 158-173	10.1	27
100	Impact of clinical characteristics on human chorionic gonadotropin regression after molar pregnancy. <i>Clinics</i> , 2021 , 76, e2830	2.3	
99	Ovarian cancer reporting lexicon for computed tomography (CT) and magnetic resonance (MR) imaging developed by the SAR Uterine and Ovarian Cancer Disease-Focused Panel and the ESUR Female Pelvic Imaging Working Group. <i>European Radiology</i> , 2021 , 1	8	5
98	A novel alternative to cytotoxic chemotherapy for gestational trophoblastic disease. <i>Lancet Oncology</i> , 2021 , 22, 1490-1491	21.7	1
97	Treatment of hydatidiform mole using manual vacuum aspiration: technical and tactical aspects. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 1299-1300	3.5	
96	Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1531-1539	2.2	15
95	Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors. <i>Gynecologic Oncology</i> , 2021 , 161, 581-586	4.9	2
94	Loss of Selenoprotein Iodothyronine Deiodinase 3 Expression Correlates with Progression of Complete Hydatidiform Mole to Gestational Trophoblastic Neoplasia. <i>Reproductive Sciences</i> , 2021 , 28, 3200-3211	3	1
93	Treatment of high-risk gestational trophoblastic neoplasia and chemoresistance/relapsed disease. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2021 , 74, 81-96	4.6	6
92	Distinct microRNA profiles for complete hydatidiform moles at risk of malignant progression. <i>American Journal of Obstetrics and Gynecology</i> , 2021 , 224, 372.e1-372.e30	6.4	7
91	Uterine artery pulsatility index and serum BMP-9 predict resistance to methotrexate therapy in gestational trophoblastic neoplasia: A cohort study. <i>Current Problems in Cancer</i> , 2021 , 45, 100622	2.3	2
90	Triaging abnormal cervical cancer screening tests using p16INK4a detection by ELISA on fresh cervical samples. <i>American Journal of Reproductive Immunology</i> , 2021 , 86, e13394	3.8	1
89	Disease Distribution at Presentation Impacts Benefit of IP Chemotherapy Among Patients with Advanced-Stage Ovarian Cancer. <i>Annals of Surgical Oncology</i> , 2021 , 28, 6705-6713	3.1	1
88	Challenges in the Treatment of Low-risk Gestational Trophoblastic Neoplasia. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2021 , 43, 503-506	1.1	0

87	Video Hysteroscopy in the Diagnosis of Molar Pregnancy in two Challenging Situations: Complete Mole with Normal hCG and Partial Mole with Early Gestational Age. <i>Journal of Minimally Invasive Gynecology</i> , 2021 , 28, 1448-1449	2.2	
86	Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study. <i>Lancet Oncology, The</i> , 2021 , 22, 1188-1198	21.7	11
85	Impact of residual disease at interval debulking surgery on platinum resistance and patterns of recurrence for advanced-stage ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 1341-1347	3.5	
84	Folinic acid rescue during methotrexate treatment for low-risk gestational trophoblastic neoplasia - How much is just right?. <i>Gynecologic Oncology</i> , 2021 , 162, 638-644	4.9	1
83	Neoadjuvant chemotherapy does not disproportionately influence post-operative complication rates or time to chemotherapy in obese patients with advanced-stage ovarian cancer. <i>Gynecologic Oncology</i> , 2020 , 159, 687-691	4.9	1
82	Outcomes in the management of high-risk gestational trophoblastic neoplasia in trophoblastic disease centers in South America. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 1366-1371	3.5	2
81	How to optimize the management of gestational trophoblastic disease during the coronavirus disease era?. <i>American Journal of Obstetrics and Gynecology</i> , 2020 , 223, 604-605	6.4	0
80	An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275. <i>Gynecologic Oncology</i> , 2020 , 158, 354-360	4.9	6
79	EMA vs EMACO in the treatment of gestational trophoblastic neoplasia. <i>Gynecologic Oncology</i> , 2020 , 158, 99-104	4.9	3
78	Gestational trophoblastic neoplasia lethality among Brazilian women: A retrospective national cohort study. <i>Gynecologic Oncology</i> , 2020 , 158, 452-459	4.9	14
77	Effectiveness and toxicity of second-line actinomycin D in patients with methotrexate-resistant postmolar low-risk gestational trophoblastic neoplasia. <i>Gynecologic Oncology</i> , 2020 , 157, 372-378	4.9	8
76	Comparison of treatment for low-risk GTN with standard 8-day MTX/FA regimen versus modified MTX/FA regimen without chemotherapy on the weekend. <i>Gynecologic Oncology</i> , 2020 , 156, 598-605	4.9	5
75	A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 6009-6009	2.2	5
74	Patient-reported and clinician-rated performance status and general health among women with gynecologic cancers on palliative chemotherapy.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e24128-e24128	2.2	
73	Association between antioxidant vitamins and oxidative stress among patients with a complete hydatidiform mole. <i>Clinics</i> , 2020 , 75, e1724	2.3	2
72	Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. <i>International Journal of Cancer</i> , 2020 , 147, 413-422	7.5	19
71	Comprehensive analysis of 204 sporadic hydatidiform moles: revisiting risk factors and their correlations with the molar genotypes. <i>Modern Pathology</i> , 2020 , 33, 880-892	9.8	12
70	Outcomes for relapsed versus resistant low risk gestational trophoblastic neoplasia following single-agent chemotherapy. <i>Gynecologic Oncology</i> , 2020 , 159, 751-757	4.9	0

69	Female adnexal tumor of probable Wolffian Origin - A report of two cases at one institution. <i>Gynecologic Oncology Reports</i> , 2020 , 33, 100612	1.3	1
68	Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. <i>Gynecologic Oncology</i> , 2020 , 159, 72-78	4.9	7
67	Use of ablation and ultrasonic aspiration at primary debulking surgery in advanced stage ovarian, fallopian tube, and primary peritoneal cancer. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 1052-1057	3.5	1
66	Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer. <i>Gynecologic Oncology Reports</i> , 2019 , 29, 118-122	1.3	7
65	The association between progesterone receptor expression and survival in women with adult granulosa cell tumors. <i>Gynecologic Oncology</i> , 2019 , 153, 74-79	4.9	1
64	Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?. <i>Gynecologic Oncology</i> , 2019 , 153, 277-285	4.9	12
63	Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer. <i>Gynecologic Oncology</i> , 2019 , 153, 471-478	4.9	10
62	A tumor board report of an 83-year-old woman with stage IB grade 3 endometrioid endometrial adenocarcinoma. <i>Current Problems in Cancer</i> , 2019 , 43, 443-449	2.3	
61	Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma. <i>International Journal of Gynecological Cancer</i> , 2019 , 29, 585-592	3.5	7
60	A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome. <i>American Journal of Obstetrics and Gynecology</i> , 2019 , 221, 326.e1-326.e7	6.4	9
59	Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 1731-1738	13.4	79
58	State-of-the-Art Workup and Initial Management of Newly Diagnosed Molar Pregnancy and Postmolar Gestational Trophoblastic Neoplasia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 1396-1401	7.3	10
57	Infection, thrombosis, and oncologic outcome after interval debulking surgery: Does perioperative blood transfusion matter?. <i>Gynecologic Oncology</i> , 2019 , 153, 63-67	4.9	11
56	The fallopian tube, "precursor escape" and narrowing the knowledge gap to the origins of high-grade serous carcinoma. <i>Gynecologic Oncology</i> , 2019 , 152, 426-433	4.9	44
55	Gestational Trophoblastic Disease Electronic Consults: What Do Patients and Physicians Want to Know?. <i>International Journal of Gynecological Cancer</i> , 2018 , 28, 824-828	3.5	4
54	Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: A case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute. <i>Gynecologic Oncology</i> , 2018 , 148, 5-11	4.9	11
53	Is chemotherapy always necessary for patients with nonmetastatic gestational trophoblastic neoplasia with histopathological diagnosis of choriocarcinoma?. <i>Gynecologic Oncology</i> , 2018 , 148, 239-246	4.9	7
52	Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience. <i>Gynecologic Oncology</i> , 2018 , 148, 161-167	4.9	34

51	Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas. <i>Journal of Pathology</i> , 2018 , 246, 344-351	9.4	33
50	Experience With the Use of an Online Community on Facebook for Brazilian Patients With Gestational Trophoblastic Disease: Netnography Study. <i>Journal of Medical Internet Research</i> , 2018 , 20, e10897	7.6	5
49	Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. <i>Gynecologic Oncology</i> , 2018 , 148, 49-55	4.9	9
48	Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. <i>Cancer Discovery</i> , 2018 , 8, 1404-1421	24.4	168
47	The impact of health insurance status on the stage of cervical cancer diagnosis at a tertiary care center in Massachusetts. <i>Gynecologic Oncology</i> , 2018 , 150, 67-72	4.9	7
46	Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery?. <i>Gynecologic Oncology</i> , 2018 , 150, 233-238	4.9	14
45	Multiple pregnancies with complete mole and coexisting normal fetus in North and South America: A retrospective multicenter cohort and literature review. <i>Gynecologic Oncology</i> , 2017 , 145, 88-95	4.9	38
44	Molar Pregnancy and Gestational Trophoblastic Neoplasia 2017 , 1-7		
43	Frequency of "incidental" serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: A six-year study. <i>Gynecologic Oncology</i> , 2017 , 146, 69-73	4.9	26
42	Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery. <i>Gynecologic Oncology</i> , 2017 , 147, 612-616	4.9	9
41	Placental site trophoblastic tumors and epithelioid trophoblastic tumors: Biology, natural history, and treatment modalities. <i>Gynecologic Oncology</i> , 2017 , 144, 208-214	4.9	67
40	Differentiated exophytic vulvar intraepithelial lesions are genetically distinct from keratinizing squamous cell carcinomas and contain mutations in PIK3CA. <i>Modern Pathology</i> , 2017 , 30, 448-458	9.8	38
39	What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study. <i>Cancer</i> , 2017 , 123, 985-993	6.4	10
38	Management and outcome of cervical cancer diagnosed in pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2017 , 216, 276.e1-276.e6	6.4	18
37	Prognostic importance of p16 status for women with vulvar squamous cell carcinoma (SCC) treated with radiotherapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5599-5599	2.2	
36	Same-Day Discharge After Laparoscopic Hysterectomy for Endometrial Cancer. <i>Annals of Surgical Oncology</i> , 2016 , 23, 178-85	3.1	30
35	Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. <i>Cancer Prevention Research</i> , 2016 , 9, 713-20	3.2	6
34	The effect of adolescence and advanced maternal age on the incidence of complete and partial molar pregnancy. <i>Gynecologic Oncology</i> , 2016 , 140, 470-3	4.9	21

33	Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. <i>JAMA Oncology</i> , 2016 , 2, 518-22	13.4	95
32	Compassionate use study of TRC105 (Endoglin Antibody) in combination with bevacizumab (Bev) in patients (pts) with refractory and metastatic choriocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e17033-e17033	2.2	1
31	Clinical Presentation of Complete Hydatidiform Mole and Partial Hydatidiform Mole at a Regional Trophoblastic Disease Center in the United States Over the Past 2 Decades. <i>International Journal of Gynecological Cancer</i> , 2016 , 26, 367-70	3.5	22
30	Effect of race/ethnicity on clinical presentation and risk of gestational trophoblastic neoplasia in patients with complete and partial molar pregnancy at a tertiary care referral center. <i>American Journal of Obstetrics and Gynecology</i> , 2016 , 215, 334.e1-6	6.4	16
29	Effect of race/ethnicity on risk of complete and partial molar pregnancy after adjustment for age. <i>Gynecologic Oncology</i> , 2016 , 143, 73-76	4.9	12
28	Prognostic importance of human papillomavirus (HPV) and p16 positivity in squamous cell carcinoma of the vulva treated with radiotherapy. <i>Gynecologic Oncology</i> , 2016 , 142, 293-8	4.9	69
27	Maternal Near Miss According to World Health Organization Classification Among Women with a Hydatidiform Mole: Experience at the New England Trophoblastic Disease Center, 1994-2013. <i>Journal of reproductive medicine, The</i> , 2016 , 61, 210-4		6
26	Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. <i>Cell</i> , 2015 , 160, 977-989	56.2	237
25	Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies. <i>Gynecologic Oncology</i> , 2015 , 138, 201-6	4.9	39
24	Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Mllerian cancer. <i>Gynecologic Oncology</i> , 2015 , 139, 407-12	4.9	9
23	Does plastic surgical consultation improve the outcome of patients undergoing radical vulvectomy for squamous cell carcinoma of the vulva?. <i>Gynecologic Oncology</i> , 2015 , 137, 60-5	4.9	12
22	Optimal management of low-risk gestational trophoblastic neoplasia. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 1293-304	3.5	14
21	NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. <i>Cancer</i> , 2015 , 121, 2156-63	6.4	32
20	Response to chemotherapy in overweight/obese patients with low-risk gestational trophoblastic neoplasia. <i>International Journal of Gynecological Cancer</i> , 2015 , 25, 734-40	3.5	3
19	Changing presentation of complete hydatidiform mole at the New England Trophoblastic Disease Center over the past three decades: does early diagnosis alter risk for gestational trophoblastic neoplasia?. <i>Gynecologic Oncology</i> , 2015 , 138, 46-9	4.9	41
18	Relationship between race and clinical characteristics, extent of disease, and response to chemotherapy in patients with low-risk gestational trophoblastic neoplasia. <i>Gynecologic Oncology</i> , 2015 , 138, 50-4	4.9	17
17	Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. <i>Journal of Clinical Oncology</i> , 2015 , 33, 937-43	2.2	162
16	Targeting VEGFRi resistance through HIF-1β suppression: Phase II clinical trial evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent platinum resistant ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS5614-TPS5614	2.2	1

15	Management Options of Gestational Trophoblastic Disease. <i>Current Obstetrics and Gynecology Reports</i> , 2014 , 3, 76-83	0.6	3
14	Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma. <i>Gynecologic Oncology</i> , 2014 , 135, 54-7	4.9	
13	Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis. <i>Gynecologic Oncology</i> , 2014 , 133, 216-20	4.9	91
12	Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. <i>Gynecologic Oncology</i> , 2014 , 132, 280-6	4.9	63
11	A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer. <i>Gynecologic Oncology</i> , 2014 , 132, 55-60	4.9	27
10	Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary. <i>Gynecologic Oncology</i> , 2014 , 132, 760-6	4.9	41
9	What is the optimal treatment for obese patients with advanced ovarian carcinoma?. <i>American Journal of Obstetrics and Gynecology</i> , 2014 , 211, 231.e1-9	6.4	8
8	Phase II, single stage, cohort expansion study of MK-2206 in recurrent endometrial serous cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5515-5515	2.2	6
7	Phase II clinical trial evaluating CRLX101 in recurrent ovarian, tubal, and peritoneal cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5581-5581	2.2	4
6	Phase II, two-stage, two-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 5524-5524	2.2	19
5	New biologic agents for the treatment of gynecologic cancers. <i>Hematology/Oncology Clinics of North America</i> , 2012 , 26, 133-56	3.1	6
4	Factors associated with an increased risk of recurrence in women with ovarian granulosa cell tumors.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 5063-5063	2.2	
3	Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Mullerian Carcinoma. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2011 , 4, 26-33		20
2	Management of adnexal masses in pregnancy. <i>Clinical Obstetrics and Gynecology</i> , 2011 , 54, 519-27	1.7	13
1	Management of gestational trophoblastic neoplasia. <i>Seminars in Oncology</i> , 2009 , 36, 181-9	5.5	26